In a recent poll, commissioned by TheraPsil, from Pollara Strategic Insights, 56% of Canadians showed top-of-mind approval for legalizing psilocybin therapy for those suffering from treatment-resistant depression (TRD). Interestingly, in early November, Oregon legalized the first state-wide psilocybin therapy program, with 55.68% voting yes. This insight also comes during a time when new research from Johns Hopkins University, indicates that “psilocybin-assisted therapy was efficacious in producing large, rapid, and sustained antidepressant effects in patients with major depressive disorder.” In addition, TheraPsil recently announced that Minister Patty Hajdu also approved the first non-palliative Canadian access to psilocybin therapy by way of a section 56 exemption. The message is clear: The Canadian public is ready to advance psilocybin therapy as a treatment option beyond end-of-life issues for those suffering from other mental health conditions such as treatment-resistant depression. As Canada continues to struggle with a mental health crisis, TheraPsil urges Minister Hajdu to consider changes to the Canadian Drugs & Substances Act which would legalize psilocybin therapy through a doctor-as-gatekeeper model, to ensure that psilocybin therapy is made available for all Canadians in medical need.
On August 4th 2020, Canada made history and international headlines when Federal Health Minister, Patty Hajdu, approved four Canadians, suffering from end-of-life distress, the right to use psilocybin for medical purposes.
Psilocybin, the active compound in ‘magic mushrooms’ can be found in dozens of mushroom varieties, and has been a controlled substance in Canada since 1974, despite mounting research from leading institutions such as Johns Hopkins University which shows that psilocybin therapy can be a safe and effective treatment option for end-of-life distress, cancer-related anxiety and most recently, major depressive disorder, among other conditions.
Following this precedent-setting decision on August 4th, 2020, TheraPsil has received an overwhelming amount of requests from patients who may benefit from psilocybin therapy and who are requesting support for their own section 56 exemptions. Not surprisingly, a portion of these inquiries come from patients who are not terminally-ill, but who are suffering from a wide range of mental health conditions including anxiety, post-traumatic stress disorder (PTSD), addictions, and treatment-resistant depression.
At the time of this report’s publishing, TheraPsil’s inclusion criteria is narrow – focusing on supporting individuals with end-of-life distress as a result of a current or past life-threatening diagnosis. However, as psilocybin therapy continues to be sought after by patients across Canada for various medical needs, we were eager to ascertain the general public’s opinion about this treatment option for symptoms other than end-of-life distress:
Would Canadians generally be accepting of this alternative, effective option for conditions other than end-of-life distress ? If given the option to vote on legalizing psilocybin therapy for other conditions, including treatment-resistant depression, what would the public decide? Are Canadians ready to open their hearts and minds to this option, especially during a time when our country is facing a serious and growing mental health and addictions crisis?
TheraPsil’s First Poll – June Survey
In June 2020, two months prior to the historic August 4th decision, TheraPsil commissioned Pollara, a leading Canadian polling company, to determine public opinion and support of legalizing psilocybin for the terminally ill. The results of this poll showed:
- Un-aided or top-of-mind approval for legalizing psilocybin mushrooms for terminally-ill Canadians was 41%. However, a 64% majority showed “acceptance”, once those who expressed “ambivalence” were included.* One-in-four disapproved (23%).
- After providing respondents with additional information, approval significantly increased to 59% (+18 points) and 78% when “ambivalent” respondents were added.
This poll was encouraging and highlighted the importance of public education, one element of TheraPsil’s four-pillar-mission, and something that TheraPsil encourages private, public, and government organizations to expand upon.
What our first Pollara poll revealed is that a national dialog on “psychedelic therapy” was underway, and achieving significant momentum. This dialog is now further validated by Oregon’s recent passing of Measure 109 which is now the first state-wide legal psilocybin therapy program expected to roll out over the next two years.
TheraPsil’s Latest Poll – October Survey
In October 2020, two months after the government began granting access to psilocybin for patients suffering from end-of-life distress (on a case-by-case basis), TheraPsil commissioned a similar poll with two main objectives:
- Re-determine public opinion on legalizing psilocybin for terminally ill patients
- Gauge public opinion on legalizing psilocybin for a new class of patients: those suffering from treatment-resistant-depression.
In the ‘October’ poll, top-of-mind approval for legalizing psilocybin for the terminally ill showed that:
- 64% of respondents approved (either strongly or somewhat) of legalizing psilocybin for the terminally ill
- 21% strongly or somewhat disapproved
- 15% were unsure or did not know
When provided with additional information on the research regarding psilocybin’s medical potential and the Minister’s August 4th decision:
- 73% of respondents approved (either strongly or somewhat) of legalizing psilocybin for the terminally ill
- 14% strongly or somewhat disapproved
- 13% were unsure or did not know
When respondents were asked to consider legalizing psilocybin for those with treatment-resistant depression (top-of-mind approval) the poll showed:
- 56% strongly or somewhat approved
- 27% strongly or somewhat disapproved
- 17% were unsure or didn’t know
Comparing the October Poll to the June Poll
- In the October poll, un-aided (or top-of-mind) approval for legalizing psilocybin mushrooms for medicinal use for terminally ill patients is 64%. This is in line with the acceptance numbers seen in June (64%). One-in-four continues to disapprove (21% in October; 23% in June).
- After providing respondents with additional information (‘educational statement’), approval significantly increased to 73% (+9pts). This is again almost in line with the acceptance numbers seen in June (78%)
- Overall, the proportion of those in favour of legalizing psilocybin for terminally ill patients remains the same since June, for both top-of-mind approval and informed approval.
- NEW DATA: A slight majority (56%) provide top-of-mid approval for legalizing psilocybin mushrooms for those with treatment-resistant depression. About a quarter (27%) disapprove.
- Respondents were not asked about their informed support for legalizing psilocybin for those with treatment-resistant depression, just top-of-mind support.
NOTE: In June, we looked at “acceptance” or expressed + tacit approval which was calculated by combining approval and ambivalence, as the those who are ambivalent largely display more positive than negative views – and if forced to make a choice between approval and disapproval, those who are ambivalent would likely choose approval over disapproval as seen in some of our other surveys. But this time, we did not include an “ambivalent” option – thus forcing respondents to make a clear decision. Therefore, here we are comparing “approval” in the October results with “acceptance” from the June results.
This poll was commissioned by TheraPsil from Pollara Strategic Insights.
This study was conducted with an online sample of 1,515 adult Canadians from October 2nd to 4th, 2020. Results from a probability sample of this size could be considered accurate to within ±2.5 percentage points, 19 times out of 20. Results have been weighted based on age, gender and region to be representative of all adult Canadians.
The exact wording of the questions asked can be seen in the appendix section, below.
Analysis & Discussion
It is encouraging that the Canadian public continues to show sustained support for legalizing psilocybin for those with a terminal illness. Minister Hajdu has now granted 13 Canadians access to psilocybin by way of section 56 exemptions. One of these individuals, Mona Strelaeff, is the first non-palliative Canadian to be granted access, indicating the Health Minister & Government’s willingness to expand access beyond end-of-life care.
When commissioning this new poll, however, we were particularly interested in understanding the public’s top-of-mind support for legalizing psilocybin for those suffering from treatment-resistant depression. In this survey, treatment-resistant depression is defined as “people who have been treated for depression with all or most available medications and procedures, but their symptoms have not improved.”
We were very pleased to discover that 56% of Canadians either somewhat or strongly approve of legalizing psilocybin for treatment-resistant depression. As mentioned earlier, this is almost identical to the approval rate/voting numbers seen in Oregon for legalizing psilocybin therapy in the first-ever state-wide program (55.7%). Furthermore, Minister Hajdu recently approved the first non-palliative Canadian access to psilocybin, showing her / the government’s willingness to support patients in distress regardless of their life expectancy.
The support for new treatment options is critical at a time when Canada is facing a growing mental health and addictions crisis. A report by the Canadian Mental Health Association, states that “In any given year, 1 in 5 people in Canada will personally experience a mental health problem or illness” and “approximately 8% of adults will experience major depression at some time in their lives.” Typical treatment options for Canadians facing depression include pharmaceuticals, such as SSRIs, and psychotherapy. However, for individuals with treatment-resistant depression, these typical treatments do not work. Canadians with TRD suffer, and have nowhere to turn.
However, past research into psilocybin therapy has revealed it could be an effective option for those suffering from TRD.
Furthermore, a very recent study from Johns Hopkins University, published in JAMA Psychiatry, indicates that “psilocybin-assisted therapy was efficacious in producing large, rapid, and sustained antidepressant effects in patients with major depressive disorder.”
Medical News Today summarized the study’s findings, noting:
- “At the time of enrollment, participants had a score of 23 in the GRID-Hamilton Depression Rating Scale (GRID-HAMD), which indicates moderate depression. After a 1-week and 1-month follow-up, participants in the immediate treatment group dropped to a score of 8, indicating mild depression.
- In the entire cohort, 67% reduced the severity of their depressive symptoms 1 week after a psilocybin treatment. This percentage grew to 71% when researchers followed up after 4 weeks.
- After 1 week, the researchers found that 58% of the cohort were no longer classified as clinically depressed. By week 4, they found that 54% of the participants were no longer classified as depressed.”
What Does This Mean for the Future of Psilocybin Therapy in Canada?
Canadians are ready to accept psilocybin therapy, not only for those with a terminal illness but also for those suffering from treatment-resistant depression.
It is not too much of a leap to suggest that the public would potentially also be receptive to psilocybin therapy for other mental health conditions, although another survey would certainly be needed to verify. Canadians need other options for their mental health, and psilocybin therapy shows great promise.
As more Canadians contact TheraPsil for support, it is clear more resources are needed to support the potentially thousands of individuals who could benefit from psilocybin therapy. Therapists across the country need to be trained in this unique modality, including experiential learning using psilocybin themselves. A legal Canada-wide psilocybin therapy program needs to exist.
TheraPsil urges Minister Hajdu to consider changes to the Canadian Drugs & Substances Act which would legalize psilocybin therapy through a doctor-as-gatekeeper model, to ensure psilocybin therapy is made available for all Canadians in medical need.
Until then, we will continue to help Canadians access psilocybin therapy through section 56 exemptions, and we will continue our advocacy work to ensure more Canadians in medical need can access this option.
- As you may know, the sale and use of psilocybin mushrooms – also known as magic mushrooms, psychedelic mushrooms, or shrooms – is currently illegal in Canada.
Overall, do you approve or disapprove of the federal government… – RANDOMIZE ORDER to avoid ordering bias]
- Legalizing psilocybin mushrooms for medicinal use by people who are suffering from a terminal illness, such as terminal cancer
- Legalizing psilocybin mushrooms for medicinal use by people who are suffering from treatment-resistant depression – that is, by people who have been treated for depression with all or most available medications and procedures, but their symptoms have not improved.
- Strongly approve
- Somewhat approve
- Somewhat disapprove
- Strongly disapprove
- Don’t know / Unsure
- Recent clinical studies have shown that psilocybin – the psychedelic compound found in magic mushrooms – has helped treat end-of-life distress for terminally ill patients. The results of the studies showed that psilocybin produced large and significant decreases in depression and anxiety, and increases in measures of quality of life, life meaning, death acceptance, and optimism.
Some terminally ill Canadians have been asking the federal government for access to psilocybin mushrooms. They argue that since Canadian law gives terminally ill patients the right to die with medical assistance, they should also give them the right to try psilocybin in an effort to improve their quality of life.
As you may know, the federal Minister of Health recently approved the use of psilocybin mushrooms for 6 terminally ill cancer patients to ease their end-of-life distress.
Thinking about this… Overall, do you approve or disapprove of the federal government legalizing psilocybin mushrooms for medicinal use by people who are suffering from a terminal illness, such as terminal cancer?
- Strongly approve
- Somewhat approve
- Somewhat disapprove
- Strongly disapprove
- Don’t know / Unsure